Skip to main content
MedPathMedPath Home
Clinical Trials/IRCT20150822023705N16
IRCT20150822023705N16
Not yet recruiting
Phase 2

Investigating the effectiveness of adding famotidine and vitamin B6 to standard drug treatment in reducing negative symptoms in patients with schizophrenia disorder: a clinical trial with a control group

Kermanshah University of Medical Sciences0 sites80 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Kermanshah University of Medical Sciences
Enrollment
80
Status
Not yet recruiting
Last Updated
3 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Schizophrenia Disorder diagnoses with negative symptoms according to Diagnostic and Statistical Manual of Mental Disorders fifth edition by a psychiatrist
  • •under treatment with aripiprazole

Exclusion Criteria

  • •Disagreement to participate in the study

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 3
The effect of famotidine on reducing the side effects of prostate cancer radiotherapy
IRCT20231121060132N1Kermanshah University of Medical Sciences50
Active, not recruiting
Not Applicable
A trial, in which subjects with type 2 diabetes, who qualify for treatment intensification, are given insulin degludec and, additionally, either liraglutide or insulin aspart, both in combination with metformin, with the largest meal. The purpose is to compare efficacy and safety of these two treatments.
EUCTR2011-001493-25-ATovo Nordisk A/S420
Active, not recruiting
Not Applicable
A trial, in which subjects with type 2 diabetes, who qualify for treatment intensification, are given insulin degludec and, additionally, either liraglutide or insulin aspart, both in combination with metformin, with the largest meal. The purpose is to compare efficacy and safety of these two treatments.Type 2 diabetesMedDRA version: 14.0Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
EUCTR2011-001493-25-DEovo Nordisk A/S420
Active, not recruiting
Not Applicable
A trial, in which subjects with type 2 diabetes, who qualify for treatment intensification, are given insulin degludec and, additionally, either liraglutide or insulin aspart, both in combination with metformin, with the largest meal. The purpose is to compare efficacy and safety of these two treatments.Diabetes tipo 2MedDRA version: 13.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
EUCTR2011-001493-25-ESovo Nordisk A/S420
Active, not recruiting
Not Applicable
A trial, in which subjects with type 2 diabetes, who qualify for treatment intensification, are given insulin degludec and, additionally, either liraglutide or insulin aspart, both in combination with metformin, with the largest meal. The purpose is to compare efficacy and safety of these two treatments.
EUCTR2011-001493-25-DKovo Nordisk A/S420